N-PEP-12

N-PEP-12 is a porcine-brain-derived peptide preparation developed by Ever Neuro Pharma (the manufacturer of Cerebrolysin) as a defined orally bioavailable analog of the parent intravenous nootropic. Cerebrolysin itself is a complex hydrolysate of porcine cerebral cortex containing approximately 25 percent free amino acids and 75 percent low-molecular-weight peptides (less than 10 kDa) administered by daily intravenous or intramuscular injection in courses of 10 to 30 days for vascular dementia, Alzheimer's disease, ischemic stroke recovery, and traumatic brain injury indications across approximately 50 jurisdictions (Europe, Asia, Russia, South America). The intravenous administration is operationally restrictive; N-PEP-12 was developed to provide a similar peptide profile in a daily oral capsule format suitable for outpatient and over-the-counter use. The published characterization describes a peptide molecular weight distribution of 1 to 10 kDa with similar amino acid composition to Cerebrolysin and shared neurotrophic activity in cortical neuron culture (BDNF and IGF-1 mimetic effects, neurite outgrowth, protection against amyloid-beta and glutamate excitotoxicity). Clinical evidence is more limited than for Cerebrolysin: published randomized trials in mild cognitive impairment (MCI) and age-associated memory impairment report modest cognitive improvements over 90 days in single-center studies. The compound is not FDA-approved; it is marketed as a dietary supplement in the United States and as a nutraceutical or medicinal food in European jurisdictions. The principal limitation on the strength of the evidence is the small number of independent clinical trials and the dominance of the manufacturer-sponsored published record. Reconstitution is not required; oral capsules contain approximately 60 mg of peptide blend.